Shared Care

Below you can find prescribing guidelines and their review dates

Principles of shared care protocols and guidelines

Acromegaly - Review date on publication of NICE guidance

Amiodarone - Review date January 2021

Attention deficit/hyperactivity disorder (ADHD) - June 2022

Azathioprine and Mercaptopurine in adults and young people over 16 years - July 2022

Bipolar disorder -  February 2023

Dalteparin - June 2021

Dementia - Prescribing of Cognitive Enhancers  -  April 2022

Denosumab (Prolia ®▼)  -  October 2022

DMARDs monitoring quick reference guide - February 2022

   Please refer to individual shared care guidelines for more detailed information

Epilepsy in adults -  February 2021

Epilepsy in children  -  September 2021

Growth hormone: The treatment of Adults with Growth Hormone (Somatropin) -  March 2021

Growth hormone - Treatment of children with recombinant human growth hormone - February 2025

Hydroxycarbamide -  To be reviewed and retired January 2021. Note - if prescribing is being directed back to secondary care, please retain hydroxycarbamide as a specialist issued drug within the patients records so you are alerted to drug/disease interactions

Hydroxychloroquine - September 2021

Hypertension – Community Pharmacy Led Hypertension Service - January 2022

Leflunomide  - October 2025

Melatonin in the treatment of sleep disorders in children  - September 2025

Methotrexate - May 2021

Modafinil – February 2025

Mycophenolate - January 2020

Nebulised Colomycin® and tobramycin in adults with non-cystic fibrosis bronchiectasis - July 2021

Parkinson’s disease - November 2016

Prostatic Cancer - Hormonal Management of Prostatic Cancer  January 2021

Rifaxamin for Hepatic Encephalopathy - January 2020

Riluzole - August 2025

Sulfasalazine - Review date extended to November 2022

SSRIs in children and young people - June 2025

Triptorelin for the treatment of Central Precocious Puberty in Children - February 2025

Last updated on 20/01/2021 by deborahmorris8